Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients

Table 4 Changes in renal function parameters and blood pressure (BP) from 1 year before mesenchymal stromal cell (MSC) infusion, baseline and the 12-month follow up

Patient parameters	Normal range	-12	Baseline	12-month	P value (RMA)	Dif 1 (BV-1yp)	P value Dif 1	Dif 2 (12 m-BV)	P value Dif 2	Dif 3 (dif2- dif1)	P valve Dif 3
SBP (mmHg)	<120	123.8 ± 9.6	125.2 ± 10.3	126.8 ± 5.7	0.55	1.3 ± 6.8	0.65	1.6 ± 5.0	0.46	NA	NA
DBP (mmHg)	60-80	77.7 ± 3.5	75.8 ± 5.6	78.8 ± 3.3	0.43	-1.8 ± 4.5	0.36	3 ± 6	0.27	NA	NA
BUN (mg/dl)	7–20.6	28.5 ± 8.6	27.8 ± 10.5	29.5 ± 7.1	0.92	-0.6 ± 12.7	0.90	1.7 ± 4.3	0.38	NA	NA
SCr (mg/dl)	0.4–1.4	2 ± 0.3	2.5 ± 0.4	2.5 ± 0.6	0.02^b	0.5 ± 0.4	0.04^b	0 ± 0.3	0.96	0.5 ± 0.5	0.05^b
eGFR^a	90–120	33.8 ± 5.3	26.7 ± 3.1	25.8 ± 6.2	0.01^b	-7.2 ± 6	0.03^b	-0.8 ± 3.9	0.62	-6.3 ± 7.5	0.09
Rt KL (cm)	10–12	NA	19.1 ± 2	19.5 ± 2	NA	NA	NA	0.4 ± 0.6	0.13	NA	NA
Lt KL (cm)	10–12	NA	18.3 ± 2.4	18.7 ± 2.6	NA	NA	NA	0.4 ± 0.4	0.06	NA	NA

BV baseline visit, 1yp 1 year prior to intervention, 12 m 12 month after baseline, RMA repeated measures ANOVA, Dif difference, SPB systolic blood pressure, mmHg millimeter of mercury, NA not applicable, DBP diastolic blood pressure, BUN blood urea nitrogen, mg/dl milligram per deciliter SCr serum creatinine, eGFR estimated glomerular filtration rate, Rt right, KL kidney length, Lt left
^aMDRD study formula (ml/min/1.73 m²)
^bSignificant

ISSN: 1757-6512